[go: up one dir, main page]

TR200001238T2 - Deri penetrasyonunu düzelten komponentler. - Google Patents

Deri penetrasyonunu düzelten komponentler.

Info

Publication number
TR200001238T2
TR200001238T2 TR2000/01238T TR200001238T TR200001238T2 TR 200001238 T2 TR200001238 T2 TR 200001238T2 TR 2000/01238 T TR2000/01238 T TR 2000/01238T TR 200001238 T TR200001238 T TR 200001238T TR 200001238 T2 TR200001238 T2 TR 200001238T2
Authority
TR
Turkey
Prior art keywords
macrolide
pro
drug
derivative
components
Prior art date
Application number
TR2000/01238T
Other languages
English (en)
Inventor
David Ormerod Anthony
Winfield Arthur
Original Assignee
Abeerdeen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abeerdeen University filed Critical Abeerdeen University
Publication of TR200001238T2 publication Critical patent/TR200001238T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

Sunulan bulus dermatolojik bir durumun tedavisi için bir makrosiklik lakton antibiyotik ya da bir immunosupresif makrolide ya da farmakolojik olarak aktif bir benzeri, türevi ya da pro-ilacini içeren lokal olarak uygulanabilen bir formülasyonuyla ilgilidir; bunun ayirt edici özelligi de ayrica bir geçirgenlik modülatörü içermesi ve bu geçirgenlik modülatörü ve makrosiklik lakton, makrolide ya da biyolojik olarak aktif olan bir analog, bunun bir türevi ya da pro-ilacinin, terapatik bir miktar deriye uygulandiginda, asgari düzeyde bir sistemik etkinin ortaya çikmasini saglayacak derecedeki göreceli miktarlarda bulunmasidir. Immunosuppressif makrolide olarak sirolimusun kullanilmasi mümkündür.
TR2000/01238T 1997-11-07 1998-11-05 Deri penetrasyonunu düzelten komponentler. TR200001238T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9723669.9A GB9723669D0 (en) 1997-11-07 1997-11-07 Skin penetration enhancing components

Publications (1)

Publication Number Publication Date
TR200001238T2 true TR200001238T2 (tr) 2001-01-22

Family

ID=10821813

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01238T TR200001238T2 (tr) 1997-11-07 1998-11-05 Deri penetrasyonunu düzelten komponentler.

Country Status (33)

Country Link
US (2) US6958153B1 (tr)
EP (2) EP1028727B1 (tr)
JP (1) JP2001522801A (tr)
KR (1) KR20010031741A (tr)
CN (1) CN1115148C (tr)
AR (1) AR014011A1 (tr)
AT (1) ATE332134T1 (tr)
AU (1) AU759326B2 (tr)
BG (1) BG104370A (tr)
BR (1) BR9815264A (tr)
CA (1) CA2309159C (tr)
CY (1) CY1105243T1 (tr)
DE (1) DE69835163T2 (tr)
DK (1) DK1028727T3 (tr)
EA (1) EA003616B1 (tr)
EE (1) EE04390B1 (tr)
ES (1) ES2268795T3 (tr)
GB (1) GB9723669D0 (tr)
GE (2) GEP20043171B (tr)
HR (1) HRP20000233A2 (tr)
HU (1) HUP0003675A3 (tr)
ID (1) ID24662A (tr)
IL (1) IL135978A0 (tr)
NO (1) NO20002078L (tr)
NZ (3) NZ520449A (tr)
PL (1) PL340710A1 (tr)
PT (1) PT1028727E (tr)
SK (1) SK6622000A3 (tr)
TR (1) TR200001238T2 (tr)
TW (1) TW557218B (tr)
UA (1) UA73274C2 (tr)
WO (1) WO1999024036A1 (tr)
ZA (1) ZA9810111B (tr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
AU3762801A (en) * 2000-03-09 2001-09-17 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
ES2325951T3 (es) 2001-08-29 2009-09-25 Pharmakodex Limited Dispositivo de administracion topica.
CN1617709A (zh) * 2001-12-13 2005-05-18 兰贝克赛实验室有限公司 克拉霉素的稳定局部制剂
ATE426414T1 (de) * 2002-05-15 2009-04-15 Endocyte Inc Vitamin-mitomycin-konjugate
EP2517730A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
EP1594484A2 (en) * 2003-02-17 2005-11-16 Cipla Ltd. Pharmaceutical patch
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307865D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
GB0307869D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20070154966A1 (en) * 2003-12-29 2007-07-05 Ronit Sagi-Eisenberg Assay for the detection of rapamycin and rapamycin analogs
CN101098854B (zh) * 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
BRPI0515378A (pt) * 2004-09-16 2008-07-22 Bayer Healthcare Ag formulações dermalmente aplicáveis para tratamento de doenças de pele em animais
BRPI0608690B8 (pt) 2005-03-10 2021-05-25 3M Innovative Properties Co uso de uma composição antimicrobiana
US8044200B2 (en) * 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
US8465724B2 (en) 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
US7704959B2 (en) * 2006-10-03 2010-04-27 Dow Pharmaceutical Sciences Azithromycin for the treatment of nodular acne
US9205080B2 (en) 2006-11-16 2015-12-08 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) * 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
EP2184997A4 (en) 2007-07-31 2010-11-03 Univ New York DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
EP2308468A1 (en) * 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
EP2515652A4 (en) * 2009-12-21 2014-11-26 B C Unlimited Liability Company COMPOSITIONS AND METHODS FOR TREATING VITILIGO
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
WO2012142145A1 (en) * 2011-04-12 2012-10-18 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
CN102552253A (zh) * 2012-01-17 2012-07-11 唯美度科技（北京）有限公司 一种祛痘用皮肤外用剂
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN04147A (tr) 2012-10-16 2015-10-16 Endocyte Inc
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
JPWO2015199248A1 (ja) * 2014-06-26 2017-04-27 国立大学法人大阪大学 発汗抑制剤
CN115645534A (zh) 2015-09-24 2023-01-31 德雷克塞尔大学 治疗或预防皮肤障碍的新型组合物和方法
FR3050206B1 (fr) 2016-04-15 2018-05-11 Engie Dispositif et procede d'hydrogenation pour produire du methanol et dispositif et procede de cogeneration de methanol et de methane de synthese
CA3032473A1 (en) 2016-08-10 2018-02-15 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
IL302385B2 (en) * 2017-01-06 2024-06-01 Palvella Therapeutics Inc Anhydrous compositions of mtor inhibitors and methods of use
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
CN113710232A (zh) 2019-02-20 2021-11-26 人工智能治疗公司 局部雷帕霉素制剂及其在治疗面部血管纤维瘤和其他皮肤病中的用途
WO2021176263A1 (en) * 2020-03-02 2021-09-10 Shanghai Aucta Pharmaceuticals Co., Ltd. Topical formulations containing mtor inhibitors
FR3112537B1 (fr) 2020-07-14 2023-03-31 Engie Dispositif et procédé de production hybride de dihydrogène de synthèse et/ou de méthane de synthèse
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31769A (en) * 1861-03-26 Water-elevator
US3376646A (en) * 1967-03-30 1968-04-09 Herman E. Radke Template tracer
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
SG46547A1 (en) * 1990-09-04 1998-02-20 Fujisawa Pharmaceutical Co Ointments containing tricyclic compounds
EP0582239B1 (de) * 1992-08-04 1999-08-04 Rhone-Poulenc Rorer Gmbh Pharmazeutische und/oder kosmetische Zubereitung
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FI90649C (fi) 1993-02-01 1994-03-10 Pauli Groenberg Menetelmä hevosen satulan sovittamiseksi hevosen selkään
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
JPH08133979A (ja) 1994-09-16 1996-05-28 Sando Yakuhin Kk 局所適用薬剤組成物
DE69525957T2 (de) * 1994-10-26 2002-11-14 Novartis Ag Verwendung eines ungesättigten Fettalkohols
US5648389A (en) * 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use

Also Published As

Publication number Publication date
ES2268795T3 (es) 2007-03-16
KR20010031741A (ko) 2001-04-16
NZ504076A (en) 2002-12-20
HUP0003675A2 (hu) 2001-04-28
TW557218B (en) 2003-10-11
NO20002078D0 (no) 2000-04-19
GEP20043171B (en) 2004-02-25
ID24662A (id) 2000-07-27
HRP20000233A2 (en) 2001-02-28
EE04390B1 (et) 2004-12-15
EP1632231A3 (en) 2008-01-23
US6958153B1 (en) 2005-10-25
UA73274C2 (en) 2005-07-15
DK1028727T3 (da) 2006-10-23
WO1999024036A1 (en) 1999-05-20
CN1278173A (zh) 2000-12-27
EP1028727B1 (en) 2006-07-05
US20050239724A1 (en) 2005-10-27
ZA9810111B (en) 1999-05-07
GEP20032884B (en) 2003-02-25
AR014011A1 (es) 2001-01-31
PT1028727E (pt) 2006-11-30
ATE332134T1 (de) 2006-07-15
BG104370A (en) 2000-12-29
NZ520449A (en) 2004-04-30
NZ530752A (en) 2005-05-27
SK6622000A3 (en) 2001-01-18
CA2309159C (en) 2009-03-17
CY1105243T1 (el) 2010-03-03
DE69835163D1 (de) 2006-08-17
EA003616B1 (ru) 2003-08-28
GB9723669D0 (en) 1998-01-07
DE69835163T2 (de) 2007-05-31
AU1040899A (en) 1999-05-31
NO20002078L (no) 2000-07-06
IL135978A0 (en) 2001-05-20
AU759326B2 (en) 2003-04-10
EE200000279A (et) 2001-10-15
EP1632231A2 (en) 2006-03-08
BR9815264A (pt) 2001-08-14
PL340710A1 (en) 2001-02-26
CA2309159A1 (en) 1999-05-20
CN1115148C (zh) 2003-07-23
EP1028727A1 (en) 2000-08-23
JP2001522801A (ja) 2001-11-20
HUP0003675A3 (en) 2001-05-28
EA200000461A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
TR200001238T2 (tr) Deri penetrasyonunu düzelten komponentler.
PT1238658E (pt) Administracao controlada de um agente activo que utiliza um sistema implantavel
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
DE69724647D1 (de) Acyclovirhaltige antiherpesarzneistift zur topischen anwendung
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
BG106030A (en) Pharmaceutical composition
TW362978B (en) Directional drug delivery stent and method of use
TR199701567T1 (tr) Rapamisin türevleri.
PT745074E (pt) Derivados 4-amino de acido micofenolico com actividade imunossupressora
BR9708735A (pt) Derivados de uréia como inibidores da enzina impdh
NZ236823A (en) Topical pharmaceutical and cosmetic compositions containing a salt of cholanic acid, a lipid and optionally a pharmaceutically or cosmetically active substance
ES2169414T3 (es) Amino-azucar citotoxico y derivados de azucares relacionados de indolopirrolocarbazoles.
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
TR199800443T1 (tr) Hidroliz yükseltici taksan hidrofobik türevleri.
ATE173627T1 (de) Medizinische zusammensetzung
DE50014257D1 (de) Kosmetische Zubereitungen enthaltend molekulare Addukte aus Biotin und/oder Biotinestern und Cyclodextrinen
ZA963743B (en) Transdermal therapeutic system (TTS) for the administration of testosterone
ATE227973T1 (de) Kosmetische, dermatologische und pharmazeutische anwendung eines terminalia catappa pflanzenextrakts
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE331730T1 (de) Neue depsipeptid-verbindung
FR2788776B1 (fr) Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
AU1747295A (en) 4-amino 6-substituted mycophenolic acid and derivatives with immunosuppressive activity
IL81508A (en) Phytopathogenic antibiotic compositions comprising rifamycin derivatives
DE69805596D1 (de) Imidazol-Derivat und dieses als aktiven Bestandteil enthaltendes Arzneimittel
TR200001133A2 (tr) Serabral asetilkolin salgılamasını zenginleştirmek için madde